

SERVICES FOR THE PERSONAL CARE INDUSTRY



FAST MULTITARGET SCREENING FOR COSMETICS SimDerma® Platform

ABOUT SimDerma[®] Platform

SimDerma[®] is a screening system that includes multiple laboratory assays. This tool has been developed to identify novel biological activities for cosmetic and skincare products.

The main objective of SimDerma® is to meet the needs and trends of cosmetic market according to scientific evidences. Therefore, SimDerma® is a dynamic tool that implements novel targets based on cosmetic industry requirements.

SimDerma[®] platform offers a wide and fast overview of ingredient activities for skin care.

Note: SimDerma[®] platform is only indicated for actives, this tool is not capable of testing end products or formulations. Furthermore, the active compounds should be soluble in water or organic solvents (e.g. DMSO). MANIFOLD ASSAYS -ONE COMPREHENSIVE SCREENING SYSTEM



BENEFITS SimDerma[®] Platform

SimDerma[®] platform offers a quick behavior overview of ingredients and extracts, speeding up the time to market for cosmetic product development.

This unique screening tool allows customers to understand the potential application for cosmetic ingredients and expand their ingredient claims supported by scientific efficacy validation.

Laboratory experiments and cosmetic claims are matched based on scientific publications and bibliography, therefore translational research is applied.

FOR FURTHER INFORMATION, PLEASE VISIT US ON: EVONIK.COM/SIMDERMA



SimDerma[®] VALUE DRIVERS:





QUICK INGREDIENT BEHAVIOR OVERVIEW scientific evaluation in a short term



FAST TIME TO MARKET through quick screening for claim substantiation SCIENTIFIC EFFICACY VALIDATION highly scientific efficacy evaluation



COMPETITIVE PRICE due to process standardization



SUPERIOR CLAIM SUPPORT data-driven innovation processes

TRANSLATIONAL & APPLIED TECHNOLOGY through the experimental targets







SimDerma[®] Platform **ASSAYS AND CELLS PORTFOLIO**

SimDerma[®] is an in vitro multiparametric platform that currently includes 30 experiments related to 17 key cosmetic targets and clustered in 7 skin claims, which are offered to better characterization of cosmetic active ingredients and extracts.

A large collection of proprietary cell lines are used in SimDerma[®] assays. Laboratory protocols developed in house have been implemented for each single assay.



ne; Il line	Wound healing Modified Fibroblast cell line; Modified Keratinocyte cell line	
ll line	Nrf2 induction: Modified Keratinocyte cell line	
vity ine	Elastase inhibition Cell free system	
ne	CB2 agonism: Modified Epithelial cell line	
ne	Tyrosinase inhibition Melanocyte cell line	
ll line	PPARy agonism Modified Epithelia cell line	
ne; Il line	Collagen induction Modified Fibroblast cell line	
1	AP-1 inhibition Modified Macrophage cell line	

SimDerma[®] CLAIMS & TARGETS

. . . .

The assays included in SimDerma® platform are focused on the main biological activity areas for cosmetic ingredient discovery. The 30 experiments included in SimDerma® are matched in 17 cosmetic targets and included in 7 different claim groups.

*Cytotoxicities are required to perform the rest of the assays.

*Required before targets: 4, 6, 8, 13, 25 and 27 **Required before targets: 5, 7, 9, 11, 22, 26 and 28 ***Required before targets: 20 and 21

	AGE-DEFYING		SENSITIVE SKIN		NOUR	NOURISHING		SKIN EVENNESS		SKIN DEFENSE				BARRIER FORTIFY			
	} ∰€	*	×	6	*	Ø	•	ix I	←‡ →	Ø	2	6	<i>S</i>			+\$\$+	٠
	Rejuvenation	Anti-wrinkle	Firming	Itching	Soothing	Skin renewal	Hydrating	Anti- hyperpigmen- tation	Blemished skin	hotoprotection	Anti-pollution	Anti- inflammatory	Anti-oxidative stress	Atopic skin	Skin barrier repair	Tissue regeneration	Anti hair loss
 Cytotoxicity in fibroblasts* Cytotoxicity in keratinocytes** Cytotoxicity in melanocytes*** 										_							
4. Proliferation in fibroblasts	•	•				•				•						•	
5. Proliferation in keratinocytes	•					•				•	•					•	
6. Wound healing in fibroblasts	•					•										•	
7. Wound healing in keratinocytes	•					•									•	•	
8. NF-κB inhibition in fibroblasts	•					•		•	•		•	•	•	•	•		
9. NF-KB signalling in keratinocytes						•			•		•	•	•	•	•		
10. IL-6 inhibition in macrophages						•			•	•	•	•		•	•		
11. Nrf2 induction in keratinocytes	•	•				•		•		•		•	•	•	•	•	
12. Antioxidant activity	•	•			•	•		•	•	•	•	•	•	•			
13. Cellular antioxidant activity	•	•			•	•		•	•	•	•	•	•	•	•		•
14. Elastase inhibition	•	•	•							•	•						
15. CB1 antagonism										•							•
16. CB1 agonism				•	•							•			•		
17. CB2 agonism				•			•					•					
18. Collagenase inhibition	•	•	•							•	•		•				
19. TRPV-1 antagonism	•	•		•	•	•	•			•	•	•		•	•		•
20. Tyrosinase inhibition in melanocytes	•							•									
21. Melanin inhibition in melanocytes	•							•									
22. Autophagy induction in keratinocytes	•					•		•		•		•	•		•		
23. PPARγ agonism	•	•				•		•		•		•	•		•		•
24. PPARα agonism	•	•				•				•		•	•	•			•
25. HIF-1 α induction in fibroblasts						•									•	•	
26. HIF-1α induction in keratinocytes	•					•			•						•	•	
27. COL1A2 induction in fibroblasts	•	•	•			•				•						•	
28. Filaggrin induction in keratinocytes	•					•	•			•	•			•	•		
29. Hyaluronidase inhibition	•	•				•	•		•	•				•		•	
30. AP-1 inhibition in macrophages	•	•				•			•	•		•		•		•	



Disclaimer: This information and any recommendations, technical or otherwise, are presented in good faith and believed to be correct as of the date prepared. Recipients of this information and recommendations must make their own determination as to its suitability for their purposes. In no event shall Evonik Operatins GmbH assume liability for damages or losses of any kind or nature that result from the use of or reliance upon this information and recommendations. Evonik Operations GmbH expressly disclaims any representations and warranties of any kind, whether express or implied, as to the accuracy, completeness, non-infringement, merchantability and/or

fitness for a particular purpose (even if Evonik Operations GmbH is aware of such purpose) with respect to any information and recommendations provided. Reference to any trade names used by other companies is neither a recommendation nor an endorsement of the corresponding product, and does not imply that similar products could not be used. Evonik Operations GmbH reserves the right to make any changes to the information and/or recommendations at any time, without prior or subsequent notice.

March 2021

Active Ingredients | BL Evonik Care Solutions **Evonik Operations GmbH | Nutrition & Care** Scientific Park of Madrid, C / Faraday 7 28049, Madrid / Spain simderma@evonik.com **evonik.com/simderma**